Phosphorylation of the oestrogen receptor α at serine 305 and prediction of tamoxifen resistance in breast cancer

Journal of Pathology

Volumn 217, Issue 3, 2009, Pages 372-379

  Holm, C ^a   Kok, M ^b   Michalides, R ^b   Fles, R ^b   Koornstra, R H T ^b   Wesseling, J ^b   Hauptmann, M ^b   Neefjes, J ^b   Peterse, J L ^b   Stal O ^c   Landberg, G ^a   Linn, S C ^b  

^a LUND UNIVERSITY   (Sweden)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Breast; Breast cancer; Drug resistance; Immunohistochemistry; Oestrogen receptor; Phosphorylation; Predictive marker; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR ALPHA; SERINE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; BREAST TUMOR; CARCINOMA; COMPARATIVE STUDY; DRUG RESISTANCE; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; PHOSPHORYLATION; RETROSPECTIVE STUDY; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, HORMONAL; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PHOSPHORYLATION; RETROSPECTIVE STUDIES; SERINE; TAMOXIFEN; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 60549097403     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2455     Document Type: Article

References (19)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-1467.
2. Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K, et al. Tamoxifen resistance by a conformational arrest of the estrogen receptor [alpha] after PKA activation in breast cancer. Cancer Cell 2004;5:597-605.
3. Wang RA, Mazumdar A, Vadlamudi RK, Kumar R. P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO J 2002;21:5437-5447.
4. Holm C, Rayala S, Jirström K, Stål O, Kumar R, Landberg G. Association between Pakl expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst 2006;98:671-680.
5. Zwart W, Griekspoor A, Rondaij M, Verwoerd D, Neefjes J, Michalides R. Classification of anti-estrogens according to intramolecular FRET effects on phospho-mutants of estrogen receptor {alpha}. Mol Cancer Ther 2007;6:1526-1533.
6. Zwart W, Griekspoor A, Berno V, Lakeman K, Jalink K, Neef jes J, et al. PKA-induced resistance to tamoxifen is associated with an altered orientation of ER towards co-activator SRC-1. EMBO J 2007;26:3534- 3544.
7. Rydén L, Jönsson P, Chebil G, Dufmats M, Fernö M, Jirström K, et al. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer 2005;41:256-264.
8. Rydén L, Jirström K, Bendahl PO, Fernö M, Nordenskjöld B, Stål O, et al. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J Clin Oncol 2005;23:4695-4704.
9. Jirström K, Stendahl M, Rydén L, Kronblad A, Bendahl PO, Stål O, et al. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res 2005;65:8009-8016.
10. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-410.
11. Kok M, Linn SC, Van Laar RK, Jansen MP, Van den Berg TM, Delahaye LJ, et al. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 2008;DOI:10.1007/S10549-008-9939-y.
12. van Ham SM, Tjin EPM, Lillemeier BF, Grüneberg U, van Meijgaarden KE, Pastoors L, et al. HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading. Curr Biol 1997;7:950-957.
13. Jirström K, Rydén L, Anagnostaki L, Nordenskjöld B, Stål O, Thorstenson S, et al. Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial. J Clin Pathol 2005;58:1135-1142.
14. Hannemann J, Kristel P, van Tinteren H, Bontenbal M, van Hoesel QG, Smit WM, et al. Molecular subtypes of breast cancer and amplification of topoisomerase IIa: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer 2006;95:1334-1341.
15. Dutch Guidelines Breast Cancer. http://www.cbo.nl/product/richtlijnen/ folder20021023121843/rl-mamma-08.pdf/view [accessed 8 September 2008].
16. Ogawa Y, Moriya T, Kato Y, Oguma M, Ikeda K, Takashima T, et al. Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut off point as the predictor for endocrine therapy. Breast Cancer 2004;11:267-275.
17. Francis P, Fleming G, Nasi ML, Pagani O, Perez E, Walley B, et al. Tailored treatment investigations for premenopausal women with endocrine responsive (ER+ and/or PgR+) breast cancer: the SOFT, TEXT, and PERCHE trials. Breast 2003;12:S44, Abstract P104.
18. Phase III randomized study of ovarian function suppression in combination with tamoxifen versus ovarian function suppres sion in combination with exemestane versus tamoxifen alone in premenopausal women with endocrine-responsive breast can cer. IBCSG-2402. http://clinicaltrials.gov/ct/ show/NCT00066690 [accessed 8 September 2008].
19. Van't Veer LJ, Dai H, Van de Vijver MJ, He YD, Hart AAM, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-535.